| Primary |
| Acute Myeloid Leukaemia |
50.0% |
| Acute Lymphocytic Leukaemia |
16.7% |
| Acute Promyelocytic Leukaemia |
14.6% |
| Leukaemia |
6.3% |
| Oesophageal Varices Haemorrhage |
4.2% |
| Acute Myelomonocytic Leukaemia |
2.1% |
| Antifungal Prophylaxis |
2.1% |
| Conjunctivitis |
2.1% |
| Hypertension |
2.1% |
|
| Endocarditis |
10.0% |
| Haematochezia |
10.0% |
| Haematuria |
10.0% |
| Rash Generalised |
10.0% |
| Sinus Tachycardia |
10.0% |
| Acute Pulmonary Oedema |
5.0% |
| Cerebellar Ataxia |
5.0% |
| Chronic Myelomonocytic Leukaemia |
5.0% |
| Multi-organ Failure |
5.0% |
| Neck Pain |
5.0% |
| Neutropenic Colitis |
5.0% |
| Pancytopenia |
5.0% |
| Respiratory Failure |
5.0% |
| Sinus Bradycardia |
5.0% |
| Vomiting |
5.0% |
|
| Secondary |
| Acute Myeloid Leukaemia |
26.6% |
| Pyrexia |
13.0% |
| Acute Promyelocytic Leukaemia |
10.5% |
| Prophylaxis |
7.7% |
| Myelodysplastic Syndrome |
5.5% |
| Acute Lymphocytic Leukaemia |
4.8% |
| Nausea |
4.6% |
| Vomiting |
4.6% |
| Product Used For Unknown Indication |
3.3% |
| Chloroma |
2.6% |
| Diffuse Large B-cell Lymphoma |
2.6% |
| Acute Myelomonocytic Leukaemia |
2.4% |
| Bipolar Disorder |
2.0% |
| Body Temperature Increased |
2.0% |
| Non-hodgkin's Lymphoma |
1.8% |
| Acute Monocytic Leukaemia |
1.3% |
| Infection Prophylaxis |
1.3% |
| Pain |
1.3% |
| Sleep Disorder |
1.1% |
| Acute Leukaemia |
0.9% |
|
| Sepsis |
10.0% |
| Myalgia |
8.0% |
| Vomiting |
8.0% |
| Benign Intracranial Hypertension |
6.0% |
| Condition Aggravated |
6.0% |
| Myocardial Infarction |
6.0% |
| Sinus Bradycardia |
6.0% |
| Endocarditis |
4.0% |
| Febrile Neutropenia |
4.0% |
| Hepatic Function Abnormal |
4.0% |
| Hepatocellular Injury |
4.0% |
| Hyperbilirubinaemia |
4.0% |
| Neutropenia |
4.0% |
| Neutropenic Colitis |
4.0% |
| Pleural Effusion |
4.0% |
| Pneumonia |
4.0% |
| Pulmonary Mycosis |
4.0% |
| Septic Shock |
4.0% |
| Venoocclusive Liver Disease |
4.0% |
| Acute Febrile Neutrophilic Dermatosis |
2.0% |
|
| Concomitant |
| Acute Myeloid Leukaemia |
18.8% |
| Product Used For Unknown Indication |
12.8% |
| Acute Promyelocytic Leukaemia |
11.9% |
| Prophylaxis |
10.6% |
| Pyrexia |
4.6% |
| Antifungal Prophylaxis |
4.2% |
| Prophylaxis Of Nausea And Vomiting |
4.0% |
| Prophylaxis Against Graft Versus Host Disease |
3.8% |
| Acute Monocytic Leukaemia |
2.9% |
| Allergy Prophylaxis |
2.9% |
| Bone Marrow Conditioning Regimen |
2.7% |
| Febrile Neutropenia |
2.7% |
| Infection Prophylaxis |
2.7% |
| Premedication |
2.7% |
| Abdominal Pain |
2.2% |
| Hypertension |
2.2% |
| Insomnia |
2.2% |
| Liver Abscess |
2.2% |
| Herpes Zoster |
2.0% |
| Vomiting |
1.8% |
|
| Interstitial Lung Disease |
22.2% |
| Vomiting |
11.1% |
| Drug Ineffective |
6.7% |
| Weight Increased |
6.7% |
| Disseminated Intravascular Coagulation |
4.4% |
| Febrile Neutropenia |
4.4% |
| Neutropenia |
4.4% |
| Pancreatitis Acute |
4.4% |
| Renal Failure |
4.4% |
| Respiratory Failure |
4.4% |
| Syncope |
4.4% |
| White Blood Cell Count Decreased |
4.4% |
| Acute Graft Versus Host Disease In Skin |
2.2% |
| Bronchitis |
2.2% |
| Coagulopathy |
2.2% |
| Drug Administration Error |
2.2% |
| Drug Resistance |
2.2% |
| Eosinophilic Pneumonia |
2.2% |
| Hiccups |
2.2% |
| Hyperbilirubinaemia |
2.2% |
|
| Interacting |
| Acute Myeloid Leukaemia |
31.3% |
| Prophylaxis |
15.6% |
| Febrile Neutropenia |
9.4% |
| Pain |
9.4% |
| Drug Use For Unknown Indication |
6.3% |
| Anxiety Disorder |
5.2% |
| Nausea |
5.2% |
| Oedema |
5.2% |
| Vomiting |
5.2% |
| Antifungal Prophylaxis |
4.2% |
| Menorrhagia |
3.1% |
|
| Drug Interaction |
30.0% |
| Cerebellar Syndrome |
20.0% |
| Dysarthria |
20.0% |
| Menorrhagia |
20.0% |
| Device Occlusion |
10.0% |
|
